MedTrace Logo

A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma

NCT00440934 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-05-06

No results posted yet for this study

Summary

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Phase I data suggest that low levels of electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of frequencies.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DEVICE

Amplitude-modulated electromagnetic fields

Sponsors & Collaborators

  • Barbault, Alexandre, M.S.

    collaborator INDIV

  • Pasche, Boris, M.D.

    lead INDIV

Principal Investigators

  • Boris Pasche, MD, PhD · Cabinet Médical Avenue de la gare 6

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440934 on ClinicalTrials.gov